RPG Life Sciences Limited (RPGLIFE)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 20 July 2026
₹3,017.1 ↑ 20.32% (1Y)

🎯 Key Takeaways

  • RPG Life Sciences Limited is a mid-sized, diversified pharmaceutical company with a strong domestic footprint and growing international presence, operating in formulations and APIs across key therapeutic areas like nephrology, rheumatology, and oncology. It has demonstrated consistent revenue growth and healthy margins, supported by strategic expansion and a focus on inorganic growth opportunities.
  • ⚠️ Exposure to regulatory and pricing pressures in international markets could impact API and formulation margins. Dependence on a few therapeutic segmen
Market Cap
₹3,792
P/E Ratio
32.9
Div Yield
0.00%
Promoter
0.0%

📖 The Story

RPG Life Sciences Limited is a mid-sized, diversified pharmaceutical company with a strong domestic footprint and growing international presence, operating in formulations and APIs across key therapeutic areas like nephrology, rheumatology, and oncology. It has demonstrated consistent revenue growth and healthy margins, supported by strategic expansion and a focus on inorganic growth opportunities. The company maintains a robust cash position and has recently signaled shareholder-friendly policies through a high-yield dividend.

📰 What's Happening

In its FY2025-26 annual report, management highlighted 8.3% revenue growth to ₹707.5 crores and an EBITDA margin of 24.4%, driven by strong performance in nephrology (55.2%) and rheumatology (40.2%) segments. The company emphasized its US$5.2 billion diversified portfolio and strategic focus on market expansion and inorganic growth. A final dividend of Rs. 24 per share (300% yield) was declared, to be paid after AGM approval on July 23, 2026, with the record date to be set post-AGM. The 19th AGM is scheduled for July 23, 2026, and the annual report is now publicly available.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has expressed confidence in sustaining growth through market expansion and inorganic opportunities, as noted in the annual report. The company is actively managing shareholder communications and regulatory compliance, including KYC updates and electronic dividend payments. No forward earnings guidance was provided in the latest filings, but the focus remains on strategic consolidation and capitalizing on therapeutic segment growth.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company MCap (₹ Cr) P/E ROCE ROE D/E
Sun Pharmaceutical Industries Limited 4.51 L Cr 41.3 20.3% 15.1% 0.03
Divi's Laboratories Limited 1.79 L Cr 72.4 22.1% 16.6% 0.00
Torrent Pharmaceuticals Limited 1.49 L Cr 80.1
Cipla Limited 1.16 L Cr 25.4 19.4% 14.6% 0.00
Dr. Reddy's Laboratories Limited 1.12 L Cr 20.0 19.7% 16.6% 0.12
Lupin Limited 1.04 L Cr 36.2
Mankind Pharma Limited 1.03 L Cr 49.2
Zydus Lifesciences Limited 1.02 L Cr 22.5
Aurobindo Pharma Limited 87,806 25.3
Laurus Labs Limited 71,455 356.8

🔗 Peer Stock Analyses

⚠️ Risk Factors

Exposure to regulatory and pricing pressures in international markets could impact API and formulation margins. Dependence on a few therapeutic segments for growth introduces concentration risk. Integration risks associated with potential acquisitions, if any, may affect execution of inorganic growth plans. Additionally, global macroeconomic and foreign exchange volatility could affect profitability of overseas operations.

📋 Recent Filings

🧠 Analyst's Read

RPG Life Sciences is executing a stable growth strategy with strong cash flows and shareholder-friendly returns, but lacks explicit forward guidance. Investors should monitor AGM outcomes, dividend payment timelines, and any updates on inorganic growth plans or international segment performance in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-20.

📡 Get AI alerts when RPGLIFE files new disclosures

Track RPGLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RPGLIFE — Free

Free account · 2 AI queries/day